Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 9/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6762461 | 0.94 | BDKRB1 (0.46) | BDKRB1LMNAKMT2AMEN1THRB | |
| SCHEMBL6764163 | 0.90 | BDKRB1 (0.42) | BDKRB1KMT2AMEN1THRBKDM4E | |
| SCHEMBL6761625 | 0.88 | BDKRB1 (0.42) | BDKRB1KMT2AMEN1THRB | |
| SCHEMBL6761750 | 0.88 | BDKRB1 (0.41) | BDKRB1KMT2AMEN1THRBKDM4E | |
| SCHEMBL5118845 | 0.88 | BDKRB1 (0.50) | BDKRB1LMNA | |
| SCHEMBL6763250 | 0.88 | BDKRB1 (0.70) | BDKRB1LMNAKMT2A | |
| SCHEMBL6762591 | 0.88 | BDKRB1 (0.52) | BDKRB1LMNAKMT2AMEN1THRB | |
| SCHEMBL6763262 | 0.87 | LMNA (0.42) | BDKRB1LMNAKMT2AMEN1THRB | |
| SCHEMBL6762653 | 0.86 | BDKRB1 (0.40) | BDKRB1KMT2AMEN1KDM4EMAPK1 | |
| SCHEMBL5119414 | 0.86 | BDKRB1 (0.51) | BDKRB1LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | BDKRB1 481/4885LMNA 3236/4885KMT2A 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.